A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1

@article{De2015ANH,
  title={A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1},
  author={Umasankar De and Soma Kundu and Nabanita Patra and Mee Young Ahn and Ji Hae Ahn and Ji Yeon Son and Jung Hyun Yoon and Hyung Ryoung Moon and Byung Mu Lee and Hyung Sik Kim},
  journal={Biomolecules \& Therapeutics},
  year={2015},
  volume={23},
  pages={434 - 441}
}
Histone deacetylase (HDAC) inhibitors are considered novel agents for cancer chemotherapy. We previously investigated MHY219, a new HDAC inhibitor, and its potent anticancer activity in human prostate cancer cells. In the present study, we evaluated MHY219 molecular mechanisms involved in the regulation of prostate cancer cell migration. Similar to suberanilohydroxamic acid (SAHA), MHY219 inhibited HDAC1 enzyme activity in a dose-dependent manner. MHY219 cytotoxicity was higher in LNCaP (IC50=0… 
View PDF
17 Citations
Highly Influential Citations
1
Background Citations
4
Methods Citations
2

Figures from this paper

17 Citations

Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.

A Mercaptoacetamide‐Based Class II Histone Deacetylase Inhibitor Suppresses Cell Migration and Invasion in Monomorphic Malignant Human Glioma Cells by Inhibiting FAK/STAT3 Signaling

The results suggest that W2 suppresses cancer cell migration and invasion by inhibiting FAK/STAT3 signaling and STAT3 translocation to the nucleus in monomorphic malignant human glioma cells.

Inhibitors of histone deacetylase as antitumor agents: A critical review.

Design of Fluorescent Coumarin-Hydroxamic Acid Derivatives as Inhibitors of HDACs: Synthesis, Anti-Proliferative Evaluation and Docking Studies

It is concluded that compounds 7c, 7e, 7f, 7i and 7j may be considered as potential anticancer agents, considering their antiproliferative properties, their effect on the regulation of the genes, as well as their capacity to dock to the active sites.

Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells

HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.

The biological consequence of HDACi panel drugs in HeLa cells is investigated, where the data suggest predominant effects are anti-mitotic rather than cytotoxic, and methodological challenges/concerns are addressed regarding plant product false-positives that arise from the signal reduction of commercial lysine development reagents.

YdjC chitooligosaccharide deacetylase homolog induces keratin reorganization in lung cancer cells: involvement of interaction between YDJC and CDC16

The collective results indicate that YDJC is involved in SPC-induced events in A549 lung cancer cells by interacting with CDC16, and suggest that suppression of YD JC or boosting of CDC16 interaction with YDjc might be a novel way to prevent progression of lung cancer.

Matrix Metalloproteinases: A challenging paradigm of cancer management.

Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach

The data mining of publicly available data and robust bioinformatic analyses are able to explore the unknown biology of malignancies by better stratify prostate cancer patients through the selection of robust long non-coding RNAs.

Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF 10 A Cells via ERK 2 June

Over the past few decades, activation of an EMT program has been proposed as the critical mechanism for the acquisition of malignant phenotypes by epithelial cancer cells, but it is still unclear what specific signals induce EMT in carcinoma cells.

References

SHOWING 1-10 OF 32 REFERENCES

A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.

Effectiveness of the Histone Deacetylase Inhibitor (S)-2 against LNCaP and PC3 Human Prostate Cancer Cells

Overall, (S)-2 has proven to be a powerful HDACi capable of inducing growth arrest, cell death and/or differentiation of LNCaP and PC3 prostate cancer cells and, due to its low toxicity and efficacy in vivo, might also be of clinical interest to support conventional prostate cancer therapy.

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

It is shown that the known effects of HDACs on differentiation and proliferation of cancer cells observed in vitro can also be confirmed in vivo.

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast

HDAC6 is a significantly correlated with ER expression and the molecular subtype, thereby supporting the estrogen regulatory property of HDAC6 and good prognostic factors for ER-positive tumors.

Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).

Based on the ability of HDACIs to regulate many signaling pathways, co-treatment of these compounds with molecular targeted drugs is a promising strategy against many types of tumors.

Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Enhances Radiosensitivity and Suppresses Lung Metastasis in Breast Cancer In Vitro and In Vivo

It is found that IR combined with SAHA showed increased therapeutic efficacy when compared with either treatment alone in MCF-7, MDA-MB-231 and 4T1 cells and SAHA not only enhances radiosensitivity but also suppresses lung metastasis in breast cancer.

Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer

Collectively, IN-2001 inhibited cell proliferation and induced apoptosis in human breast cancer cells and these findings may provide new therapeutic approaches, combination of antiestrogen together with a HDAC inhibitor, in the hormonal therapy-resistant ER-negative breast cancers.

Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate.

The role of histone deacetylases in prostate cancer

The molecular mechanism(s) through which HDACs influence prostate cancer progression, and the potential roles of HDAC inhibitors in prostate cancer prevention and therapy are discussed.

Suppression of lung cancer cell invasion and metastasis by connexin43 involves the secretion of follistatin-like 1 mediated via histone acetylation.